Pranaya Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 26-06-2024
- Paid Up Capital ₹ 1.00 Cr
as on 26-06-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 18.75 Cr
as on 26-06-2024
About Pranaya Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹18.75 Cr.
Kanigiri Gade, Govinda Balineni, Kumaraswamy Maruri, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24239TG2020PTC139841
- Company No.
139841
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2020
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
K.V.Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Pranaya Pharmaceuticals?
Board Members(5)
Financial Performance and Corporate Structure Insights of Pranaya Pharmaceuticals.
Enhance accessibility to Pranaya Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Pranaya Pharmaceuticals?
Unlock access to Pranaya Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Akron Formulations India Private Limited
Active
39 years 1 month Kumaraswamy Maruri is a mutual person
Admiron Life Sciences Private Limited
Active 13 years 9 months Kanigiri Gade and Govinda Balineni are mutual person
Pranaya Life Sciences Private Limited
Active 6 years 6 months Kanigiri Gade and Govinda Balineni are mutual person
Safe Pharmaceuticals Pvt Ltd
Active 42 years 6 months Kanigiri Gade and Sanagala Reddy are mutual person
Pranaya Parenterals Private Limited
Active 4 years 2 months Kanigiri Gade and Sanagala Reddy are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 08 Nov 2021 | ₹18.75 Cr | Open |
How Many Employees Work at Pranaya Pharmaceuticals?
Unlock and access historical data on people associated with Pranaya Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 05, 2021, Pranaya Pharmaceuticals has raised a total of ₹ 6.59 Cr, with the most recent deal valued at ₹ 7.18 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
